Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ACTINIC KERATOSIS Clear all
Completed Not applicable Interventional Results available

Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure

NCT03315286
View directory record Official record
Conditions
Skin Cancer, Actinic Keratoses, Ultraviolet-Induced Change in Normal Skin, Behavior, Health, Behavior, Risk Reduction
Interventions
SHADE Ultraviolet Sensor, Standard of care counseling
Device · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 16, 2026, 10:45 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Combination Topical Therapy for Treatment of Scalp Actinic Keratoses

NCT03996252
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Calcipotriene 0.005% Foam, Efudex 5% Topical Cream
Drug
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Photodynamic Therapy in Treating Patients With Skin Cancer

NCT00002975
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous Condition
Interventions
aminolevulinic acid
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Not listed Phase 3 Interventional

T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum

NCT00002811
View directory record Official record
Conditions
Precancerous Condition
Interventions
liposomal T4N5 lotion
Drug
Lead sponsor
Applied Genetics
Industry
Eligibility
2 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
7
States / cities
Miami Beach, Florida • Ann Arbor, Michigan • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

NCT01428297
View directory record Official record
Conditions
Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions
BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

NCT05583669
View directory record Official record
Conditions
Netherton Syndrome
Interventions
DS-2325a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients

NCT01056107
View directory record Official record
Conditions
Irritable Bowel Syndrome Constipation Predominant
Interventions
ROSE-010, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

NCT03914417
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod 3.75% Cream
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study

NCT00952783
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Orange Park, Florida • Newnan, Georgia • Snellville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
View directory record Official record
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil

NCT02938715
View directory record Official record
Conditions
Actinic Keratosis
Interventions
teledermatology feedback
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed No phase listed Observational Results available

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

NCT02699190
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Photodynamic Therapy Incubation Times for Actinic Keratosis

NCT03066843
View directory record Official record
Conditions
Actinic Keratoses
Interventions
ALA (5-aminolevulinic acid), Blue light therapy
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses?

NCT01159860
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
cryosurgery, Curettage
Procedure
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

NCT02549339
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT02547363
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional

DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients

NCT03110159
View directory record Official record
Conditions
Skin Cancer, Non-melanoma Skin Cancer, Sun Damaged Skin, Actinic Keratosis
Interventions
Levulan® Kerastick®, BLU-U Blue Light Photodynamic Therapy
Drug
Lead sponsor
Medical Dermatology Specialists
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video

NCT02062853
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Video Group, Verbal Group
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Use of Microneedles in Photodynamic Therapy

NCT01812837
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Microneedle, Aminolevulinic Acid, Blue light
Device · Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 16, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis

NCT02337205
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 16, 2026, 10:45 AM EDT